{
    "clinical_study": {
        "@rank": "131308", 
        "arm_group": [
            {
                "arm_group_label": "PXVX0200 10E8 then placebo", 
                "arm_group_type": "Experimental", 
                "description": "PXVX0200 10E8 on day 0; Placebo on day 14"
            }, 
            {
                "arm_group_label": "Placebo, then PXVX0200 10E8", 
                "arm_group_type": "Experimental", 
                "description": "Placebo on day 0; PXVX0200 10E8 on day 14"
            }, 
            {
                "arm_group_label": "PXVX0200 10E9 then Placebo", 
                "arm_group_type": "Experimental", 
                "description": "PXVX0200 10E9 on day 0; Placebo on day 14"
            }, 
            {
                "arm_group_label": "Placebo then PXVX0200 10E9", 
                "arm_group_type": "Experimental", 
                "description": "Placebo on day 0; PXVX0200 10E9 on day 14"
            }, 
            {
                "arm_group_label": "Shanchol", 
                "arm_group_type": "Active Comparator", 
                "description": "Two doses of Shanchol, on day 0 and day 14"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare  the ability of a single dose of PXVX0200 at two different dose levels, to\n      placebo to elicit a significant antibody response 14 days after vaccination, compared to\n      baseline.\n\n      To compare the ability of a single dose of PXVX0200 to a comparator vaccine Shanchol, a two\n      dose administration, to elicit antibody response by 14 days after vaccination."
        }, 
        "brief_title": "PXVX0200 (CVD103-HgR) vs Shanchol in Mali", 
        "condition": "Cholera", 
        "condition_browse": {
            "mesh_term": "Cholera"
        }, 
        "detailed_description": {
            "textblock": "Currently there are two licensed inactivated vibrio oral vaccines (Dukoral\u00ae [Crucell;\n      Leiden, The Netherlands] and Shanchol\u2122 [Shantha Biotechnics; Hyderabad, India]) that are\n      pre-qualified by the World Health Organization (WHO) for procurement by United Nations (UN)\n      agencies.  Each of these vaccines requires a two-dose regimen which is difficult to\n      implement in the face of explosive outbreaks of cholera in unsettled situations in\n      developing countries.  For this reason there is great interest in identifying a cholera\n      vaccine that can provide rapid onset of protection following the ingestion of just a single\n      oral dose.\n\n      This Phase 2 randomized, observer-blinded and subject-blinded clinical trial to be conducted\n      in Bamako, Mali will assess the immunogenicity of the 10^8 cfu versus the 10^9 cfu\n      formulation of PaxVax-manufactured CVD 103-HgR."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able to understand the study and give consent (either written or through a process\n             that involves audio tapes explaining all aspects of the study and the consent form in\n             local languages [Bambara and French] followed by making a mark and signature by a\n             literate witness)\n\n          -  Healthy men or women, age 18 to 45 years (inclusive) without significant medical\n             history\n\n          -  Women of child-bearing potential must have negative urine pregnancy test at baseline,\n             prior to vaccination. They must also be willing to use adequate birth control for the\n             duration of the 28-day study and have additional pregnancy tests if indicated.\n             Effective methods of birth control for this study include abstinence, intrauterine\n             device (IUD), oral or depot contraceptive, or barrier plus spermicide\n\n          -  Willingness to remain in the study area until at least 42 days after receipt of the\n             first vaccine dose\n\n        Exclusion Criteria:\n\n          -  Health care workers who have direct contact with patients who are immune deficient,\n             HIV-positive, or have an unstable medical condition\n\n          -  Clinically significant history of immunodeficiency, cardiovascular disease,\n             respiratory disease, endocrine disorder, liver disease, renal disease,\n             gastrointestinal disease, neurologic illness, psychiatric disorder requiring\n             hospitalization, current drug or alcohol abuse\n\n          -  History of an abnormal stool pattern or regular use of laxatives\n\n          -  Previously received a licensed or investigational cholera vaccine\n\n          -  History of cholera illness"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02145377", 
            "org_study_id": "HP-00059690"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "PXVX0200 10E8 then placebo", 
                    "Placebo, then PXVX0200 10E8"
                ], 
                "description": "Oral dose of PXVX0200 10E8", 
                "intervention_name": "PXVX0200 10E8", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "PXVX0200 10E9 then Placebo", 
                    "Placebo then PXVX0200 10E9"
                ], 
                "description": "Oral dose of  PXVX0200 10E9", 
                "intervention_name": "PXVX0200 10E9", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "PXVX0200 10E8 then placebo", 
                    "Placebo, then PXVX0200 10E8", 
                    "PXVX0200 10E9 then Placebo", 
                    "Placebo then PXVX0200 10E9"
                ], 
                "description": "Oral dose of sodium bicarbonate buffer", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Shanchol", 
                "description": "Licensed comparator", 
                "intervention_name": "Shanchol", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cholera", 
            "Vaccine", 
            "Mali"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "contact": {
                "email": "ssow@medicine.umaryland.edu", 
                "last_name": "Samba O Sow, MD"
            }, 
            "contact_backup": {
                "email": "mtapia@medicine.umaryland.edu", 
                "last_name": "Milagritos Tapia, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Bamako", 
                    "country": "Mali"
                }, 
                "name": "Centre pour le D\u00e9veloppement des Vaccins, Mali (CVD-Mali)"
            }, 
            "investigator": [
                {
                    "last_name": "Samba O Sow, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Milagritos Tapia, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Mali"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase 2 Randomized, Double-Blinded Study to Compare in Malian Adults the Immunogenicity, Clinical Acceptability and Excretion Pattern Following the Ingestion of a Single Dose of PXVX0200 (CVD 103-HgR) Live Oral Cholera Vaccine Containing Either 108 Colony Forming Units [Cfu] or 109 Cfu Using Shanchol\u2122 Killed Whole Cell Oral Cholera Vaccine as an Immunological Comparator", 
        "other_outcome": [
            {
                "description": "To plot the seroconversion (\u2265 4-fold increase over baseline), mean fold rise (comparing baseline titer with post-vaccination titer), and kinetics of serum IgG cholera antitoxin antibody following the ingestion of a single oral dose of PXVX0200 (CVD 103-HgR) containing \u22652 x10E8 cfu or \u22652 x10E9 cfu versus Shanchol\u2122.", 
                "measure": "Plot seroconversion", 
                "safety_issue": "No", 
                "time_frame": "Day 7, 14, 21, 28, 35 and 42"
            }, 
            {
                "description": "Assess tiredness, vomiting, loss of appetite, abdominal pain and headache", 
                "measure": "Assess reactogenicity", 
                "safety_issue": "Yes", 
                "time_frame": "For seven days after each dose of PXVX0200"
            }
        ], 
        "overall_contact": {
            "email": "mtapia@medicine.umaryland.edu", 
            "last_name": "Milagritos Tapia, MD", 
            "phone": "410-706-5328"
        }, 
        "overall_contact_backup": {
            "email": "ssow@medicine.umaryland.edu", 
            "last_name": "Samba O Sow, MD"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Maryland", 
                "last_name": "Milagritos D Tapia, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre pour le Developpement des Vaccins - Mali", 
                "last_name": "Samba O Sow, MD, MS", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Mali: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A comparison of the ability of a single \u22652 x10E9 cfu oral dose versus a single \u22652 x10E8 cfu oral dose of PXVX0200 (CVD 103-HgR) versus placebo to elicit a significant (> 4-fold) rise in serum Inaba vibriocidal antibody 14 days after vaccination, compared to baseline", 
            "measure": "To elicit a significant rise in serum Inaba vibriocidal antibody after a single vaccination", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02145377"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Maryland", 
            "investigator_full_name": "Milagritos Tapia", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare the ability of a single \u22652 x108 cfu dose of PXVX0200 (CVD 103-HgR) or \u22652 x109 oral dose of PXVX0200 (CVD 103-HgR) versus Shanchol\u2122 to elicit serum Inaba vibriocidal antibody mean fold rise (compared to baseline titer) and GMT", 
                "measure": "To measure antibody response for a 10E8 dose and 10E9 dose of PXVX0200 oral vaccine", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "To plot the kinetics of the serum Inaba vibriocidal antibody response after ingestion of a single oral dose of PXVX0200 (CVD 103-HgR) containing \u22652 x10E8 cfu or \u22652 x10E9 cfu versus Shanchol\u2122. (With GMT on the Y axis and time points on the X axis, the GMTs at baseline and at each post-vaccination time point will be connected as a line graph).", 
                "measure": "To plot the kinetics of the serum Inaba Vibriocidal antibody response", 
                "safety_issue": "No", 
                "time_frame": "Baseline and post-vaccination time point."
            }, 
            {
                "description": "Shedding of CVD 103-HgR in stool as determined by stool culture (whole specimen or rectal swab)", 
                "measure": "Assess fecal shedding of PXVX0200", 
                "safety_issue": "No", 
                "time_frame": "Day 1-3, day 7 and day 14"
            }, 
            {
                "description": "To compare the rate of diarrhea (\u2265 4 loose stools within 24 hours) following administration of each vaccine regimen versus placebo over 7 days of follow-up", 
                "measure": "Compare rate of diarrhea", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }
        ], 
        "source": "University of Maryland", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "PaxVax, Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Shantha Biotechnics Limited", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Maryland", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}